Tirzepatide, initially developed to combat type 2 diabetes, has demonstrated additional benefits in safeguarding the cardiovascular system and acting as a powerful weight loss adjunct. It is a synthetic analog of gastric inhibitory polypeptide (GIP) with concurrent glucagon-like peptide-1 (GLP-1) functionality. This dual action enables Tirzepatide to reduce blood glucose levels, enhance insulin sensitivity, promote satiety, and expedite weight reduction.
Lot-traced · COA on file · Sterility & mycoplasma tested
PEPTIDE DOSE: Select dose
DRAW SYRINGE TO: Select values
YOUR VIAL CONTAINS: Select values
CONCENTRATION: Select values
Tirzepatide is a dual-acting peptide that targets both GIP and GLP-1 receptor pathways, making it a significant focus in metabolic research. Scientists study its potential effects on glucose utilization, insulin signaling, appetite regulation, and body composition.
By activating these complementary pathways, Tirzepatide may support research involving metabolic efficiency, energy expenditure, and weight-management mechanisms. Its innovative dual-receptor activity distinguishes it from traditional single-pathway peptide compounds.
Apply once, get reviewed by our team, and access provider-only pricing across peptides, exosomes, and cellular products.
PRODUCT USAGE: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product is intended strictly for laboratory research and qualifies under appropriate regulatory frameworks for research-only use. It is not intended to diagnose, treat, cure, or prevent any disease or condition. This product should only be handled by licensed, qualified professionals. It is not intended for use by the general public. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
